Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M6,783Revenue (TTM) $M624Net Margin (%)-43.9Altman Z-Score6.9
Enterprise Value $M6,506EPS (TTM) $-1.8Operating Margin %-43.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.1Pre-tax Margin (%)-43.4Higher ROA y-yN
Price/Book5.310-y EBITDA Growth Rate %--Quick Ratio3.5Cash flow > EarningsY
Price/Sales10.75-y EBITDA Growth Rate %--Current Ratio3.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-293.8ROA % (ttm)-14.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-20.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M151ROIC % (ttm)-27.4Gross Margin Increase y-yY

Gurus Latest Trades with ALKS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALKSVanguard Health Care Fund 2016-03-31 Add0.13%$29.05 - $79.38
($40.36)
$ 45.1112%Add 25.56%8,603,676
ALKSGeorge Soros 2016-03-31 Sold Out -0.01%$29.05 - $79.38
($40.36)
$ 45.1112%Sold Out0
ALKSKen Fisher 2016-03-31 Reduce$29.05 - $79.38
($40.36)
$ 45.1112%Reduce -0.02%120,297
ALKSGeorge Soros 2015-12-31 Reduce-0.01%$57.89 - $80.14
($70.39)
$ 45.11-36%Reduce -56.96%3,400
ALKSVanguard Health Care Fund 2015-12-31 Reduce$57.89 - $80.14
($70.39)
$ 45.11-36%Reduce -0.40%6,851,996
ALKSKen Fisher 2015-12-31 Add$57.89 - $80.14
($70.19)
$ 45.11-36%Add 0.34%120,327
ALKSVanguard Health Care Fund 2015-09-30 Add0.08%$55.08 - $72.79
($66.01)
$ 45.11-32%Add 10.43%6,879,583
ALKSGeorge Soros 2015-09-30 Buy 0.01%$55.08 - $72.79
($66.01)
$ 45.11-32%New holding7,900
ALKSKen Fisher 2015-09-30 Add$55.08 - $72.79
($66.01)
$ 45.11-32%Add 11.90%119,920
ALKSVanguard Health Care Fund 2015-03-31 Add$58.24 - $73.64
($68.32)
$ 45.11-34%Add 0.05%6,229,583
ALKSKen Fisher 2014-12-31 Add$40.23 - $58.88
($51.09)
$ 45.11-12%Add 10.18%107,164
ALKSVanguard Health Care Fund 2014-12-31 Add$40.23 - $58.88
($51.09)
$ 45.11-12%Add 0.05%6,226,383
ALKSVanguard Health Care Fund 2014-09-30 Add0.01%$41.54 - $51.75
($44.82)
$ 45.111%Add 1.42%6,223,083
ALKSKen Fisher 2014-09-30 Add$41.54 - $51.52
($44.73)
$ 45.111%Add 75.86%97,264
ALKSVanguard Health Care Fund 2014-06-30 Add0.13%$41.1 - $50.94
($46.06)
$ 45.11-2%Add 18.45%6,135,913
ALKSKen Fisher 2014-06-30 Buy 0.01%$41.1 - $50.94
($46.06)
$ 45.11-2%New holding55,309
ALKSVanguard Health Care Fund 2014-03-31 Add0.19%$40.07 - $53.82
($47.32)
$ 45.11-5%Add 41.07%5,180,238
ALKSVanguard Health Care Fund 2013-12-31 Add0.1%$30.17 - $41.12
($36.93)
$ 45.1122%Add 28.18%3,672,087
ALKSVanguard Health Care Fund 2013-09-30 Add0.07%$28.66 - $35.35
($32.58)
$ 45.1138%Add 26.21%2,864,896
ALKSJoel Greenblatt 2013-09-30 Sold Out -0.03%$28.66 - $35.35
($32.58)
$ 45.1138%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALKS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALKS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MITCHELL PAUL JDirector 2016-06-06Sell2,000$44.980.29view
MITCHELL PAUL JDirector 2016-05-04Sell2,000$38.616.87view
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc. 2016-04-20Sell16,875$41.099.78view
POPS RICHARD FDirector and CEO, Alkermes plc 2016-04-19Sell18,750$40.1512.35view
Brown Iain MichaelVP Finance & CAO, Alkermes Inc 2016-04-18Sell5,368$39.2714.87view
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. 2016-04-13Sell11,698$37.6619.78view
POPS RICHARD FDirector and CEO, Alkermes plc 2016-04-12Sell25,000$37.7919.37view
MITCHELL PAUL JDirector 2016-04-04Sell2,000$35.6526.54view
POPS RICHARD FDirector and CEO, Alkermes plc 2016-03-22Sell25,000$31.7741.99view
POPS RICHARD FDirector and CEO, Alkermes plc 2016-03-15Sell25,000$31.443.66view

Quarterly/Annual Reports about ALKS:

News about ALKS:

Articles On GuruFocus.com
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 
Weekly Guru Bargains Highlights: Coinstar Inc, Fair Isaac Corp, Alkermes Inc, American International Dec 12 2009 

More From Other Websites
Alkermes Plc – Value Analysis (NASDAQ:ALKS) : June 21, 2016 Jun 21 2016
Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 20, 2016 Jun 20 2016
ALKERMES PLC. Files SEC form 8-K, Other Events Jun 08 2016
ETF’s with exposure to Alkermes Plc : June 8, 2016 Jun 08 2016
ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers Jun 02 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes Rises on Evercore’s ‘Buy’ Rating, Buying Support Jun 01 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes Plc Conference Call to Discuss Data and Study Design from FORWARD-3 and FORWARD-4 Studies... Jun 01 2016
ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... May 26 2016
Alkermes Begins Phase I Study on Immuno-Oncology Drug May 26 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Initiates Phase 1 Clinical Trial Of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
ETF’s with exposure to Alkermes Plc : May 24, 2016 May 24 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)